Trial Profile
Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 06 Oct 2020
Price :
$35
*
At a glance
- Drugs Alpha 1-antitrypsin (Primary)
- Indications Graft-versus-host disease
- Focus Expanded access; Therapeutic Use
- 30 Sep 2020 Status changed from recruiting to completed.
- 07 Jun 2017 New trial record